Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS).

Hatton et al. (2005) looked at the dysbindin gene (DTNBP1) in kids with early-onset psychosis. They wanted to know if tiny DNA changes in this gene track with poor early-life social and school skills. The team used standard genetic tests and the Premorbid Adjustment Scale to measure childhood functioning.

Certain DTNBP1 variants showed up more often in children who later developed psychosis. These same kids had lower PAS scores, meaning they already struggled socially and academically before the first psychotic break. The link points to dysbindin as one of the earliest risk flags.

Schirmbeck et al. (2008) tried to repeat the finding in adults. They tested 36 dysbindin markers in over 200 German patients with adult-onset schizophrenia. Result: no link at all. The two studies seem to clash, but the gap is age. Childhood-onset cases may need the gene defect to get sick, while adult-onset cases do not.

Davison et al. (1984) adds a biochemical angle. They found plasma cyclic AMP doubled in kids with autism and PDD. Together the papers sketch two early warning systems: one genetic (DTNBP1) and one chemical (cAMP), both measurable long before full-blown symptoms.

Singh et al. (2025) rounds out the picture. Their 2025 review shows other genes shape how kids respond to antipsychotics. Knowing a child carries DTNBP1 risk variants could guide safer medicine choices later on.

If you assess young children with language delays, social slips, or odd play, consider asking the medical team for dysbindin screening. A positive result won't predict psychosis with certainty, but it flags higher risk and justifies tighter developmental follow-up, parent coaching, and perhaps gentler medication trials when the time comes.